Eli Lilly drug prolongs survival in large lung cancer trial

(Reuters) - Eli Lilly and Co's cancer drug ramucirumab modestly extended survival in a large, late-stage study of patients with advanced, nonsmall cell lung cancer who had relapsed following initial treatment, according to data presented on Saturday.

via Reuters: Health News Read More Here..